NCT05265052 2026-03-11
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
3D Medicines
Phase 2 Not yet recruiting
3D Medicines
Wake Forest University Health Sciences
M.D. Anderson Cancer Center